SKELAXIN
Pronunciation: me-TAX-a-loen


What it isCentral muscle relaxant of uncertain mechanism; acute musculoskeletal spasm.
Why this oneIt impairs alertness less than many skeletal muscle relaxants, but direct evidence of benefit is unusually thin.
What limits itFood raises exposure, and alcohol or opioids amplify sedation; rare hemolytic anemia and hepatotoxicity occur.
Animated chart of estimated U.S. prescriptions per year, Muscle relaxants (1950–2026). Metaxalone enters in 1962 (estimated).
Principal riskWeak efficacy evidence; take with food
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acute painful musculoskeletal conditions (adjunct) | Adults & pediatric ≥13 yr | 800 mg TID–QID | 800 mg TID–QID | 800 mg QID |
Renal Contraindicated in significantly impaired renal function
Hepatic Contraindicated in significantly impaired hepatic function
Available strengths
Pregnancy Safe use not established; should not be used in women who are or may become pregnant, particularly in early pregnancy, unless benefit outweighs hazard
Lactation Undefined
Generic entry2010
Provisional washout figures
Elevating mechanismMAO-A inhibitor
Non-elevating actionNone recorded
Exposure dependencePrimarily supratherapeutic/overdose exposure
Washout AFTER an MAOIU days
Evidence confidenceModerate
InterpretationWeak MAO-A inhibition, most relevant at supratherapeutic or overdose exposure.
Open Metaxalone in the interactive console ↗

Open Metaxalone in the interactive console ↗